Tendinopathy: Disorders that are causes by overuse of tendons.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
175 |
4. Check minimum number of eventsNone |
175 |
5. Include endpointsNone |
175 |
6. Filter based on genotype QC (FinnGen only) |
171 |
Control definitions (FinnGen only)
- Control exclude
- M13_DORSOPATHY
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- M76
- Name in latin
- Tendinitis musculi psoae
Similar endpoints
↥List of similar endpoints to
Psoas tendinitis
based on the number of shared cases.
Similar with more cases:
- Enthesopathies of lower limb, excluding foot
- Soft tissue disorders
- Dorsopathies
- Diseases of the musculoskeletal system and connective tissue
- Any operation in hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 827 | 506 | 319 |
| Only index persons | 808 | 498 | 310 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 48.04 | 49.29 | 46.15 |
| Only index persons | 47.94 | 49.19 | 45.94 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 171 | 117 | 54 |
| Unadjusted period prevalence (%) | 0.04 | 0.04 | 0.02 |
| Median age at first event (years) | 54.95 | 53.97 | 57.07 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 175
- Matched controls
- 1750
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M76.1
ICD-10 Finland
Psoas tendinitis
+∞
250.9
175
*
NF1AA
NOMESCO Finland
Hip X-ray examination
14.1
46.8
49
47
M16.1
ICD-10 Finland
Other primary coxarthrosis
9.0
36.0
54
83
NE1BG
NOMESCO Finland
Pelvic, hip and femur MRI examination with high intensity magnet
45.5
34.7
42
12
L13
ICPC
Hip symptom/complaint
6.5
31.1
70
163
NA3BG
NOMESCO Finland
Lumbar spine MRI examination with high intensity magnet
43.3
28.7
35
10
M51.1
ICD-10 Finland
Lumbar and other intervertebral disc disorders with radiculopathy
33.2
27.0
35
13
M16.0
ICD-10 Finland
Primary coxarthrosis, bilateral
10.2
26.7
33
39
N03AX16
ATC
[U] pregabalin
6.3
26.6
57
125
M51.3
ICD-10 Finland
Other specified intervertebral disc degeneration
45.2
22.5
27
7
N06AX21
ATC
duloxetine; oral
6.9
22.0
39
70
N02AX02
ATC
tramadol; systemic, rectal
4.5
21.6
96
375
M25.5
ICD-10 Finland
Pain in joint
4.4
20.9
90
342
M79.6
ICD-10 Finland
Pain in limb
4.3
20.3
108
475
NFF25
NOMESCO Finland
Cleaning of hip joint, arthroscopic
118.6
20.0
21
*
M48.0
ICD-10 Finland
Spinal stenosis
36.1
19.9
25
8
N03AX12
ATC
[U] gabapentin; oral
5.8
18.6
39
82
NFB30
NOMESCO Finland
Primary total prosthetic replacement of hip joint not using cement
7.9
17.5
26
38
NE1AA
NOMESCO Finland
Pelvis X-ray examination
8.0
16.5
24
34
M76.0
ICD-10 Finland
Gluteal tendinitis
27.7
16.5
22
9
M01AH05
ATC
etoricoxib; oral
4.3
15.9
136
780
NK5AT
NOMESCO Finland
Joint injection with ultrasound guidance not elsewhere classified
49.8
15.4
18
*
XX2AT
NOMESCO Finland
Other injection with ultrasound examination
35.2
15.2
19
6
A02BC05
ATC
esomeprazole; systemic
3.5
14.9
93
430
M70.6
ICD-10 Finland
Trochanteric bursitis
4.6
14.7
41
109
NFG00
NOMESCO Finland
Arthroplasty of hip joint
163.0
14.7
15
*
M54.5
ICD-10 Finland
Low back pain
3.6
14.7
70
273
NE1CG
NOMESCO Finland
Pelvic, hip and femur extensive MRI examination with high intensity magnet
28.4
13.7
18
7
NJ3NA
NOMESCO Finland
Measurement of difference in extremity lengty with X-ray
43.8
13.4
16
*
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
3.4
13.3
67
268
M54.4
ICD-10 Finland
Lumbago with sciatica
4.5
13.3
37
98
N02AE01
ATC
buprenorphine; parenteral, sublingual, transdermal
6.0
13.2
25
47
NFE15
NOMESCO Finland
Plastic repair of capsule or ligament of hip joint
+∞
12.6
12
*
R10.4
ICD-10 Finland
Other and unspecified abdominal pain
3.2
12.6
86
410
M75.1
ICD-10 Finland
Rotator cuff syndrome
3.4
12.6
61
237
M54.9
ICD-10 Finland
Dorsalgia, unspecified
5.0
12.5
30
70
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.4
12.2
60
235
A02BC02
ATC
pantoprazole; systemic
3.5
11.9
134
842
NE1BA
NOMESCO Finland
Pelvis extensive X-ray examination
25.0
11.8
16
7
R4110, ,
SPAT
5.2
11.6
26
57
Q65.88
ICD-10 Finland
Other congenital deformities of hip
+∞
11.6
11
*
M47.2
ICD-10 Finland
Other spondylosis with radiculopathy
128.1
11.6
12
*
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
11.1
10.8
20
20
NA3CG
NOMESCO Finland
Lumbar spine extensive MRI examination with high intensity magnet
64.0
10.8
12
*
M16
ICD-10 Finland
Coxarthrosis [arthrosis of hip]
9.2
10.7
22
27
L03
ICPC
Low back symptom/complaint
3.2
10.6
54
214
ABC36
NOMESCO Finland
Decompression of lumbar nerve roots
+∞
10.5
10
*
Y83
ICD-10 Finland
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
5.7
10.1
20
39
R5110, ,
SPAT
5.5
9.8
20
40
N02BF01
ATC
gabapentin; oral
5.3
9.1
19
39
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
3.9
8.5
27
78
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
6.9
8.3
20
32
M23.9
ICD-10 Finland
Internal derangement of knee, unspecified
3.7
8.2
28
85
NBG15
NOMESCO Finland
Acromioplastia, arthroscopic
4.7
8.2
20
47
NF1DA
NOMESCO Finland
X-ray of hips
13.9
8.0
13
10
Z01.8
ICD-10 Finland
Other specified special examinations
2.9
8.0
47
199
N02AA59
ATC
codeine, combinations excl. psycholeptics; systemic
2.5
7.9
82
460
NFL30
NOMESCO Finland
Transposition of muscle of hip or thigh
19.4
7.7
11
6
NF2AT
NOMESCO Finland
Injection to hip joint with ultrasound guidance
26.3
7.7
10
*
M16.3
ICD-10 Finland
Other dysplastic coxarthrosis
26.3
7.7
10
*
L01
ICPC
Neck symptom/complaint
3.2
7.5
34
124
NFL22
NOMESCO Finland
Myotomy or tenotomy of hip or thigh
83.5
7.5
8
*
UDQ12
NOMESCO Finland
Flexible laryngoscopy
6.3
7.5
19
33
A02BC01
ATC
omeprazole; systemic
2.6
7.4
53
248
M01AX05
ATC
glucosamine; oral
2.9
7.3
41
169
M01AH01
ATC
celecoxib; oral
3.1
7.3
34
126
M03BX02
ATC
tizanidine; oral
2.5
7.3
121
827
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
4.2
7.2
20
52
M50.1
ICD-10 Finland
Cervical disc disorder with radiculopathy
14.6
7.0
11
8
EB1HA
NOMESCO Finland
Panorama tomography of teeth and jaws or similar X-ray examination
2.3
6.9
86
515
N02BF02
ATC
pregabalin; oral
7.7
6.9
15
21
S76.1
ICD-10 Finland
Injury of quadriceps muscle and tendon
23.6
6.7
9
*
M54.8
ICD-10 Finland
Other dorsalgia
9.3
6.7
13
15
M01AE02
ATC
naproxen; oral, rectal
2.3
6.7
114
776
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
10.6
6.6
12
12
WX320
NOMESCO Finland
Spinalanesthesy
2.5
6.6
53
261
R10.1
ICD-10 Finland
Pain localized to upper abdomen
2.8
6.6
39
165
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
3.6
6.5
23
71
Z03.9
ICD-10 Finland
Observation for suspected disease or condition, unspecified
2.7
6.4
40
173
R10.3
ICD-10 Finland
Pain localized to other parts of lower abdomen
2.5
6.4
53
263
SHA01
NOMESCO Finland
Stomatognathic treatment, simple
3.1
6.4
30
111
M02AA10
ATC
ketoprofen; topical
2.9
6.4
33
129
M02AA07
ATC
piroxicam; topical
2.3
6.4
67
370
N02BE01
ATC
paracetamol; systemic, rectal
4.3
6.4
163
1332
N02AJ06
ATC
codeine and paracetamol; systemic
2.2
6.3
81
486
NA3EA
NOMESCO Finland
Lumbar spine X-ray examination with flexion
+∞
6.3
6
*
J01DB01
ATC
cefalexin; oral
3.2
6.3
155
1233
K21.9
ICD-10 Finland
Gastro-oesophageal reflux disease without oesophagitis
3.4
6.2
24
79
L89
ICPC
Osteoarthrosis of hip
7.1
6.2
14
21
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
83
382
3.23
13.03
2.4
2.2
52.71
55.44
u/l
0.44
77
353
71
301
3.29
12.75
2.5
2.0
—
—
—
0
0
90
465
2.93
11.08
3.4
2.9
18.65
36.67
ng/l
1.13
50
289
148
1017
3.95
10.82
5.6
3.4
9.85
10.35
mm/h
0.21
143
936
109
633
2.91
10.64
2.9
2.2
—
—
—
0
0
151
1099
3.73
9.04
4.6
3.8
14.75
14.60
pmol/l
0.32
136
998
53
234
2.81
8.38
1.6
1.3
15.84
31.18
iu/ml
1.26
21
80
145
1050
3.22
8.34
7.3
6.7
71.47
76.26
u/l
0.83
137
979
51
224
2.80
8.12
1.4
1.3
17.29
8.24
u/ml
0.24
22
86
42
176
2.82
7.24
4.5
3.9
33.68
32.97
%
0.14
31
113
116
785
2.42
7.03
6.8
9.5
3.71
3.94
e9/l
0.66
96
690
80
477
2.25
6.35
1.8
1.8
109.21
99.82
pmol/l
0.86
38
244
95
608
2.23
6.33
7.6
6.4
1.22
1.22
mmol/l
0.60
84
528
91
575
2.21
6.22
14.4
8.4
1.19
1.16
inr
0.09
21
184
167
1437
4.54
6.20
18.0
10.5
18.60
21.98
mg/l
0.71
148
1074
57
309
2.25
5.57
2.6
2.9
864.73
817.31
ng/l
0.06
48
267
168
1474
4.49
5.50
18.6
11.9
3.95
3.94
mmol/l
0.17
163
1425
57
315
2.20
5.28
2.9
2.5
332.04
4616.37
umol/l
1.32
50
279
161
1344
3.47
5.26
6.0
4.5
1.70
2.78
mu/l
0.64
148
1227
95
640
2.06
5.20
4.4
3.2
0.00
0.00
estimate
-0.00
13
137
95
643
2.04
5.11
4.4
3.2
0.00
0.02
estimate
0.50
12
123
82
527
2.05
5.08
2.1
2.2
80.82
74.80
nmol/l
1.16
71
471
93
643
1.95
4.53
6.8
4.5
0.00
0.01
estimate
0.50
11
132
11
19
6.10
4.52
1.7
1.4
—
—
—
0
0
128
993
2.08
4.41
3.0
3.2
—
—
—
0
0
104
758
1.92
4.21
3.8
3.9
6.28
6.70
mmol/l
1.42
97
687
126
982
2.01
4.15
3.4
2.7
53.47
42.71
u/l
0.44
117
924
81
549
1.89
4.06
6.2
5.1
1.23
1.22
mmol/l
0.88
71
501
175
1655
+∞
3.81
25.2
16.2
40.48
40.38
%
0.15
168
1571
49
286
1.99
3.79
2.5
1.9
2.50
3.13
mg/l
1.86
40
243
7
9
8.04
3.59
1.0
1.2
—
—
—
0
0
160
1398
2.69
3.51
5.1
4.0
5.81
5.85
mmol/l
0.16
142
1274
170
1567
3.97
3.36
11.9
8.8
24.14
25.79
u/l
1.00
163
1507
11
28
4.12
3.35
1.4
1.2
—
—
—
0
0
34
186
2.03
3.11
1.6
1.6
1120.64
1133.58
nmol/l
0.02
22
137
45
272
1.88
3.10
1.6
1.5
0.65
0.94
mg/l
0.91
34
206
158
1404
2.29
2.77
15.4
9.9
81.74
86.07
ml/min/173m2
1.66
129
1126
72
514
1.68
2.77
4.6
3.3
—
—
—
0
0
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
6
10
6.17
2.72
1.0
1.2
—
—
—
0
0
50
325
1.75
2.69
1.4
1.2
0.83
1.00
u/ml
0.21
13
81
33
194
1.86
2.45
3.4
2.3
4.21
3.99
e6/l
0.03
19
104
23
120
2.06
2.39
1.7
1.8
331.35
402.71
nmol/l
0.99
23
112
60
422
1.64
2.39
4.3
2.7
—
—
—
0
0
7
17
4.24
2.38
2.0
1.6
—
—
—
0
0
7
17
4.24
2.38
2.0
1.6
—
—
—
0
0
7
17
4.24
2.38
2.0
1.6
—
—
—
0
0
7
17
4.24
2.38
2.0
1.6
—
—
—
0
0
11
40
2.86
2.32
1.7
1.6
—
—
—
0
0
7
18
4.00
2.27
2.0
1.6
—
—
—
0
0
7
18
4.00
2.27
2.0
1.6
—
—
—
0
0
5
9
5.68
2.23
1.8
2.0
—
—
—
0
0
5
9
5.68
2.23
1.0
1.1
—
—
—
0
0
17
81
2.22
2.21
2.7
2.2
0.01
0.08
e6/l
1.63
17
75
8
24
3.44
2.21
1.5
1.1
—
—
—
0
0
13
55
2.47
2.18
2.8
3.8
1.83
2.36
mmol/l
—
8
46
160
1457
2.15
2.16
5.1
4.5
2.89
2.80
mmol/l
0.66
143
1353
47
319
1.65
2.12
1.8
1.5
—
—
—
0
0
12
50
2.50
2.07
1.5
1.7
—
—
—
0
0
8
26
3.17
2.04
1.9
1.5
—
—
—
0
0
32
199
1.74
1.98
3.1
2.2
1.27
1.19
e6/l
0.06
18
106
5
11
4.64
1.95
1.6
1.1
—
—
—
0
0
5
11
4.64
1.95
1.6
1.1
—
—
—
0
0
12
52
2.40
1.92
1.3
1.9
—
—
—
0
0
7
22
3.27
1.90
1.4
1.5
—
—
—
0
0
40
268
1.64
1.89
1.5
1.4
18.34
22.32
nmol/l
1.13
34
229
157
1436
1.91
1.85
4.5
4.0
4.89
4.73
mmol/l
1.14
142
1340
68
518
1.51
1.85
5.0
3.8
36.46
36.40
g/l
0.03
61
488
23
133
1.84
1.81
5.0
6.3
104.13
104.90
mmol/l
0.29
23
133
12
54
2.31
1.78
2.9
2.1
0.59
0.72
%
0.73
12
54
6
18
3.41
1.76
1.0
1.1
—
—
—
0
0
152
1382
1.76
1.75
4.2
3.6
1.27
1.25
mmol/l
0.15
137
1280
145
1305
1.65
1.71
6.6
5.2
38.94
39.40
mmol/mol
0.26
133
1210
10
40
2.59
1.69
3.2
3.8
25.17
25.91
mmol/l
—
10
40
12
56
2.23
1.65
2.9
2.1
0.91
1.17
%
0.73
12
56
5
14
3.64
1.62
5.8
2.3
67.00
54.36
%
—
5
14
13
65
2.08
1.53
1.8
1.4
—
—
—
0
0
155
1430
1.73
1.52
4.8
4.0
1.55
1.52
mmol/l
0.36
140
1327
5
16
3.18
1.45
1.0
1.0
—
—
—
0
0
11
53
2.15
1.42
5.7
2.8
40.58
50.52
%
0.51
11
53
25
161
1.64
1.38
2.5
6.0
—
—
—
0
0
5
17
3.00
1.37
1.0
1.1
—
—
—
0
0
46
343
1.46
1.34
3.7
3.3
0.00
0.03
estimate
0.68
12
129
10
48
2.15
1.30
2.4
1.5
—
—
—
0
0
16
92
1.81
1.30
1.3
1.2
70.56
139.81
u/ml
1.12
16
84
20
124
1.69
1.27
3.6
4.5
2.13
42.58
ug/l
0.57
15
95
8
36
2.28
1.26
1.4
1.3
—
—
—
0
0
17
102
1.74
1.21
1.3
1.2
227.50
155.26
iu/ml
—
6
44
27
184
1.55
1.20
1.7
1.7
—
—
—
0
0
26
178
1.54
1.14
1.9
2.0
—
—
—
0
0
34
247
1.47
1.13
1.7
1.8
424.89
435.78
pmol/l
0.10
28
207
29
205
1.50
1.10
1.9
2.2
—
—
—
0
0
7
35
2.04
1.01
1.4
1.3
—
—
—
0
0
7
35
2.04
1.01
2.3
2.3
—
—
—
0
0
25
176
1.49
0.97
1.8
1.6
30.52
29.29
s
0.49
25
171
41
319
1.37
0.94
4.0
2.5
0.30
0.49
e6/l
0.55
29
227
13
78
1.72
0.94
1.4
2.4
17.15
60.52
u/ml
0.82
13
73
6
27
2.26
0.94
1.3
1.4
—
—
—
0
0
9
52
1.77
0.94
4.6
6.9
23.97
24.87
mmol/l
—
9
52
14
87
1.66
0.90
2.6
1.5
—
—
—
0
0
10
58
1.77
0.81
1.6
1.4
—
—
—
0
0
5
25
2.03
0.73
1.8
1.4
—
12.50
—
0
5
5
25
2.03
0.73
1.0
1.8
—
—
—
0
0
15
101
1.53
0.73
1.0
3.1
84.57
67.61
ml/min/173m2
—
7
38
28
218
1.34
0.65
4.4
2.9
17.06
408.40
ng/l
0.75
18
155
0
20
0.00
0.61
0.0
1.6
—
—
—
0
0
0
22
0.00
0.59
0.0
2.1
—
—
—
0
0
0
22
0.00
0.59
0.0
1.6
—
—
—
0
0
0
23
0.00
0.58
0.0
1.6
—
—
—
0
0
13
90
1.48
0.57
1.0
1.0
—
—
—
0
0
32
261
1.28
0.55
4.0
3.7
24.33
20.93
%
0.63
15
123
45
386
1.22
0.51
3.8
4.0
1.55
9.95
mg/mmol
2.85
30
246
16
120
1.37
0.48
1.9
1.6
—
—
—
0
0
15
112
1.37
0.46
2.3
1.8
0.25
0.22
g/l
0.61
15
104
16
121
1.35
0.46
2.0
1.7
—
—
—
0
0
23
187
1.26
0.41
3.8
2.8
0.93
0.74
ug/l
0.24
13
124
0
16
0.00
0.41
0.0
1.7
—
—
—
0
0
5
34
1.48
0.40
1.0
1.2
—
—
—
0
0
9
66
1.38
0.39
1.2
1.3
—
—
—
0
0
6
41
1.48
0.36
1.2
1.1
—
—
—
0
0
12
152
0.77
0.31
1.5
1.7
—
—
—
0
0
31
273
1.16
0.27
1.5
1.5
—
—
—
0
0
5
73
0.68
0.26
1.4
2.3
—
—
—
0
0
6
81
0.73
0.24
3.3
2.2
147.50
109.14
ng/l
—
6
74
6
84
0.70
0.24
1.2
1.5
—
—
—
0
0
5
37
1.36
0.23
2.4
1.4
—
—
—
0
0
5
40
1.26
0.22
1.4
1.1
—
—
—
0
0
5
40
1.26
0.22
1.4
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
6
49
1.23
0.20
2.7
1.8
—
—
—
0
0
47
438
1.10
0.18
3.0
3.2
2.35
2.35
mmol/l
0.09
41
394
126
1291
0.91
0.17
21.6
13.3
16.81
14.64
%
2.02
126
1269
11
126
0.86
0.11
4.0
2.9
—
—
—
0
0
12
117
1.03
0.00
2.1
1.9
—
—
—
0
0
7
73
0.96
0.00
1.4
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
9
0.00
-0.00
0.0
2.2
—
112.89
—
0
9
9
98
0.91
-0.00
2.0
1.7
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
3.2
—
141.60
—
0
5
0
9
0.00
-0.00
0.0
1.8
—
15.00
—
0
9
0
9
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
(3011547) Coagulation factor VII activity actual/normal in Platelet poor plasma by Coagulation assay
0
8
0.00
-0.00
0.0
1.0
—
131.25
—
0
8
0
5
0.00
-0.00
0.0
1.2
—
122.80
—
0
5
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint M13_PSOASTEND and mortality.
Females
No dataMales
No dataMortality risk
Mortality risk for people of age
years, who have M13_PSOASTEND.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | No data |
| 5 | No data | No data |
| 10 | No data | No data |
| 15 | No data | No data |
| 20 | No data | No data |
Relationships between endpoints
↥Index endpoint: M13_PSOASTEND – Psoas tendinitis
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data